Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author’s right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage. [http://researchspace.auckland.ac.nz/feedback](http://researchspace.auckland.ac.nz/feedback)

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.
INSULIN-LIKE GROWTH FACTORS
IN THE ISCHAEMIC HEART

A thesis submitted in partial fulfilment of the
requirements for the degree of
Doctor of Philosophy
at the
University of Auckland
by
KENNETH GEORGE MATTHEWS

The University of Auckland

2001
Abstract

Cardiac muscle has very limited ability to regenerate following injury. Loss of muscle due to myocardial infarction (MI) is therefore compensated for by hypertrophy of the surviving cardiac muscle. Deposition of inflexible scar tissue in the infarct zone leads to subsequent dysfunction of the heart, often culminating in chronic morbidity and eventual death due to heart failure.

Insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II) are members of a family of insulin-related peptides involved in tissue development, repair and replacement. Their involvement in these roles has been clearly demonstrated in skeletal muscle, but remains unclear in cardiac muscle. The aim of this thesis, therefore, was to undertake a comprehensive evaluation of the insulin-like growth factor axis following induced MI in sheep, in order to determine the relationship between time-based changes in the myocardium and insulin-like growth factor levels, and subsequently to determine the therapeutic effect of GH or IGF-I treatment on cardiac function following MI.

To achieve the aims of the thesis, a model of MI was developed from the existing cardiology technique of percutaneous transluminal coronary angioplasty. Using this model, MI was induced in adult ewes by selected coronary artery occlusion under fluoroscopic guidance. Subsequently, the model was further developed into one of stable heart failure, utilising serial microembolisations targeted by echocardiography.
Results showed that, in the cardiomyocytes bordering the infarct, IGF-I mRNA, protein and receptor binding increased, whereas IGF-II mRNA and protein levels did not vary, although IGF-II receptor binding increased.

Following these findings, IGF-I levels were manipulated by subcutaneous injections of either growth hormone or IGF-I, and by intra-pericardial IGF-I delivery via catheter.

Results showed that neither growth hormone nor subcutaneous IGF-I were able to effect an improvement in cardiac function, although there were indications that a longer duration of treatment with subcutaneous IGF-I might have done so. Intra-pericardial IGF-I, however, resulted in a significant and sustained improvement in cardiac function.

In conclusion, surviving cardiomyocytes at the infarct border show marked changes in IGF-I localisation, production and specific binding, indicating that IGF-I is directly involved in post-infarct events, possibly in the maintenance of cardiac function by the induction of hypertrophy. Delivery of IGF-I directly into the pericardium results in a significant improvement in left ventricular ejection fraction which is sustained after cessation of treatment. Such a result indicates that IGF-I may have a role as a therapy in the failing heart.
Acknowledgements

My thanks must go firstly to those who have supervised my progress through the sometimes difficult years of my research, my chief supervisor, Associate Professor John Bass, and my co-supervisor, Associate Professor John Conaglen. Also to Dr Gerry Devlin, whose clinical expertise in cardiology made the whole project possible. Thanks to all three of you for sharing your knowledge, keeping me on track, and putting up with my tantrums when things fell apart. Without you all, this thesis would never have eventuated.

Thanks also to Merv Aitken, for teaching me in the shortest possible time the skills required to be a radiographer. Special thanks to Selwyn Stuart, for his patient care of the animals and tireless efforts in the x-ray suite, also to Ross Lasenby and Trevor Watson for their assistance with the animals.

A heartfelt thanks to Juliet Jensen, who put up with endless changes of plan and still arrived (almost) on time to capture the essential ultrasound images without which much of this work would not have been possible.

Many people assisted me in the laboratory by passing on their skills, and I thank them all, but in particular, Drs Ravi Kambadur, Mridula Sharma and Gina Nicholas for introducing me to the mysteries of molecular biology, not forgetting Brett Langley for his good-humoured and patient tuition in the same field. Also in the laboratory, my heartfelt thanks to Dr Jenny Oldham and to Melanie Whittle and Sonnie Kirk, who had to put up with me in my earliest efforts at laboratory work. Thanks, too, to Darylyn Hurford and Pete Fowke for their contribution to my enlightenment.
A special thank you to Dr Neil Cox for his patient assistance with statistical analyses, and to Dr Rob Doughty for his independent analysis of the echocardiography studies.

Finally, thanks to all those who I haven’t had room to mention by name. Your many contributions made this work possible.

The studies in this thesis were funded by several bodies. My thanks to Medlab, Hamilton; The Waikato Medical Research Foundation, The Laugesen Trust; The National Heart Foundation of New Zealand and the Chiron corporation.
Table of Contents

Abstract ........................................................................................................... ii
Acknowledgements ....................................................................................... iv
Table of Contents .......................................................................................... vi
List of Figures ................................................................................................ xii
List of Tables .................................................................................................. xiv
List of Abbreviations ..................................................................................... xv

CHAPTER 1 ..................................................................................................... 1

1.1 THE INSULIN-LIKE GROWTH FACTORS .................................................. 1
  1.1.1 A Brief History of IGF-I & IGF-II ....................................................... 2
  1.1.2 IGF Structure .................................................................................... 3

1.2 THE HEART ............................................................................................. 5
  1.2.1 Pre-Natal Heart Development ............................................................. 6
  1.2.2 The Cardiomyocyte .......................................................................... 7

1.3 THE IGFs IN THE HEART ........................................................................ 11
  1.3.1 IGF Message and Protein ................................................................. 11
  1.3.2 IGF Receptors in the Heart ............................................................... 12
  1.3.3 The IGFs and the Cell Cycle ............................................................ 15
  1.3.4 The IGFs and Post-Natal Cardiac Development ............................... 21
  1.3.5 IGF Regulation ................................................................................. 24

1.4 MYOCARDIAL INFARCTION .................................................................. 32
  1.4.1 The IGF Axis Post-Infarct ................................................................. 36
  1.4.2 Possible Post-Infarct Roles of the IGFs ............................................ 37

1.5 HEART FAILURE ..................................................................................... 41
1.5.1 Therapeutic Roles for IGF-I in Ischaemic Heart Failure ................. 43

1.6 SUMMARY ................................................................................. 46

1.7 THE AIM OF THIS THESIS ........................................................ 46

1.7.1 Achieving the Aim of the Thesis ............................................. 47

CHAPTER 2 ................................................................................. 48

2.1 MATERIALS ........................................................................... 48

2.1.1 Peptides and Hormones ....................................................... 48

2.1.2 Antibodies .......................................................................... 49

2.1.3 Molecular Probes ............................................................... 49

2.1.4 Enzymes ............................................................................ 51

2.1.5 Radioisotopes ................................................................. 51

2.1.6 Other Reagents ................................................................. 52

2.2 COMPOSITION OF SOLUTIONS ............................................. 53

2.2.1 In Situ Hybridisation Buffers ............................................... 54

2.2.2 Northern Hybridisation Buffer ............................................ 54

2.2.3 Receptor Autoradiography Buffers ................................. 55

2.2.4 Immunohistochemistry Buffers .......................................... 55

2.2.5 Other Solutions ................................................................. 56

2.3 EXPERIMENTAL METHODS .................................................. 57

2.3.1 In Situ Hybridisation (Molenaar et al. 1992) ..................... 57

2.3.2 Immunohistochemistry (Hsu et al. 1981) ......................... 61

2.3.3 Receptor Binding Studies (Elliott et al. 1992) .................... 64

2.3.4 Radioimmunoassay (Hodgkinson et al. 1991a) ................ 66

2.3.5 Western Ligand Blot (Hossenlopp et al. 1986) ............... 69

2.3.6 Northern Analysis (Sambrook et al. 1989) ....................... 71
2.3.7 Image Analysis ................................................................. 73
2.3.8 Photomicrography ............................................................ 74
2.3.9 Statistical Analyses ........................................................... 74

CHAPTER 3 ............................................................................. 75

3.1 THE AIM OF THE DEVELOPMENT PHASE .................................. 75
3.2 MYOCARDIAL INFARCTION ..................................................... 76
   3.2.1 The Sheep ......................................................................... 76
   3.2.2 Induction of Myocardial Infarction ..................................... 78
3.3 STABLE HEART FAILURE ....................................................... 86
   3.3.1 Method of Induction .......................................................... 86
   3.3.2 Echocardiography ............................................................. 89
3.4 RESULTS .................................................................................. 92
   3.4.1 Induction of Infarction ....................................................... 92
   3.4.2 Echocardiography ............................................................. 102
   3.4.3 Conclusions ............................................................... 103

CHAPTER 4 ............................................................................. 105

4.1 INTRODUCTION ...................................................................... 105
4.2 THE AIM OF THIS CHAPTER .................................................. 107
4.3 METHODS .............................................................................. 107
   4.3.1 The Animal Model .......................................................... 107
   4.3.2 Descriptive Histology ....................................................... 108
   4.3.3 Immunohistochemistry .................................................... 108
   4.3.4 Receptor Binding Studies ............................................... 109
   4.3.5 In Situ Hybridisation ...................................................... 109

viii
CHAPTER 5

5.1 INTRODUCTION ......................................................................................... 138
5.2 THE AIM OF THIS CHAPTER .................................................................... 139
5.3 METHODS ................................................................................................. 140
5.3.1 The Animal Model ... ......................................................................... 140
5.3.2 Descriptive Histology ......................................................................... 141
5.3.3 Radioimmunoassay – IGF-I Protein ..................................................... 141
5.3.4 Northern Analysis ................................................................................ 143
5.3.5 Western Ligand Blot - IGFBPs ............................................................ 144
5.3.6 Echocardiography .............................................................................. 145
5.3.7 Statistical Analysis .............................................................................. 145
5.4 RESULTS .................................................................................................. 146
5.4.1 Induction of Myocardial Infarction ........................................ 146
5.4.2 Descriptive Histology ...................................................... 147
5.4.3 Radioimmunoassay – IGF-I Protein ..................................... 150
5.4.4 Northern Analysis ............................................................ 154
5.4.5 Western Ligand Blot - IGFBPs ........................................... 159
5.4.6 Echocardiography ............................................................ 163
5.5 DISCUSSION ..................................................................... 164
  5.5.1 Plasma IGF-I Levels ....................................................... 164
  5.5.2 Cardiomyocyte Hypertrophy ............................................. 164
  5.5.3 Cardiac IGF-I ................................................................. 166
  5.5.4 Cardiac Function ............................................................ 168
  5.5.5 Conclusions ................................................................. 171

CHAPTER 6 ........................................................................... 173

6.1 INTRODUCTION ............................................................... 173
6.2 THE AIM OF THIS CHAPTER ............................................ 174
6.3 METHODS ...................................................................... 175
  6.3.1 The Animal Model ........................................................ 175
  6.3.2 Radioimmunoassay – IGF-I Protein ................................ 179
  6.3.3 Western Ligand Blot - IGFBPs ....................................... 180
  6.3.4 Echocardiography ........................................................ 180
  6.3.5 Statistical Analysis ......................................................... 182
6.4 RESULTS ......................................................................... 182
  6.4.1 Induction of Stable Heart Failure ................................. 182
  6.4.2 Radioimmunoassay of Plasma IGF-I .............................. 182
  6.4.3 Western Ligand Blot - IGFBPs ...................................... 188
6.4.4 Echocardiography .................................................. 190
6.5 DISCUSSION ............................................................ 197
  6.5.1 Plasma IGF-I Levels ............................................ 197
  6.5.2 Cardiac Function ............................................... 199
  6.5.3 Conclusions ..................................................... 205

CHAPTER 7 ........................................................................... 206

  7.1 SUMMARY OF THE RESEARCH ............................... 206
  7.2 CONCLUSIONS ....................................................... 216
  7.3 FUTURE WORK ........................................................ 223

References ........................................................................ 224

Publications Arising From This Thesis ................................. 248
List of Figures

Figure 1-1 Cyclins and Cyclin-Dependent Kinases in the Cell Cycle ..................18
Figure 3-1 Sheep Coronary Arteries .........................................................77
Figure 3-2 The Waves of the ECG .............................................................83
Figure 3-3 Typical Sampling Areas ...........................................................85
Figure 3-4 Post-Infarct Changes in ECG Pattern ........................................93
Figure 3-5 Post-Infarct Myocardial Enzyme Profiles ..................................95
Figure 3-6 Hearts Displaying Evidence of Myocardial Infarction ..................97
Figure 3-7 Normal and Remodelled Sheep Heart .......................................99
Figure 3-8 Heart 60 Days Post-Infarct ......................................................100
Figure 3-9 Dilated and Normal Hearts ......................................................101
Figure 4-1 Time Course of Post-Infarct Tissue Changes ..............................112
Figure 4-2 Normal and Hypertrophied Cardiomyocytes ...............................113
Figure 4-3 Cardiomyocyte Area of Non-Infarcted and Infarcted Animals .......114
Figure 4-4 Immunohistochemistry Controls ..............................................116
Figure 4-5 Increased IGF-I Immunostaining at Infarct Border .....................117
Figure 4-6 Immunostaining for IGFBP-2 ....................................................117
Figure 4-7 IGF-I Immunohistochemistry Time Course ..................................118
Figure 4-8 IGF-I mRNA ............................................................................121
Figure 4-9 Comparison of Displacement by IGF-I and by des(1-3) IGF-I .........123
Figure 4-10 IGF-I Receptor Binding ..........................................................124
Figure 4-11 IGF-II Receptor Binding ..........................................................126
Figure 4-12 Ligand Blot of Myocardial IGFBPs ..........................................128
Figure 4-13 Islands of Tissue .....................................................................133
Figure 5-1 Heart 30 Days Post-Infarct .......................................................146
List of Tables

Table 3-1 Left Ventricular Ejection Fraction ................................................. 102
Table 5-1 Heart Weight Index ........................................................................ 146
Table 5-2 IGF-I Receptor – Mean Optical Densities ..................................... 157
Table 5-3 Growth Hormone Receptor – Mean Optical Densities .................. 158
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALS</td>
<td>acid-labile subunit</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine-5-triphosphate</td>
</tr>
<tr>
<td>BP</td>
<td>binding protein</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>cDNA</td>
<td>complementary deoxyribonucleic acid</td>
</tr>
<tr>
<td>Ci</td>
<td>Curie</td>
</tr>
<tr>
<td>cm</td>
<td>centimetre</td>
</tr>
<tr>
<td>CPM</td>
<td>counts per minute</td>
</tr>
<tr>
<td>C-terminal</td>
<td>carboxyl terminal</td>
</tr>
<tr>
<td>CV</td>
<td>coefficient of variation</td>
</tr>
<tr>
<td>Cx</td>
<td>circumflex (coronary artery)</td>
</tr>
<tr>
<td>Da</td>
<td>Dalton</td>
</tr>
<tr>
<td>DAB</td>
<td>diaminobenzidine</td>
</tr>
<tr>
<td>DEPC</td>
<td>diethyl pyrocarbonate</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSS</td>
<td>disuccinimidyl suberate</td>
</tr>
<tr>
<td>E.coli</td>
<td>Escherichia coli</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiograph</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylene diaminetetra-acetic acid disodium salt</td>
</tr>
<tr>
<td>EF</td>
<td>ejection fraction</td>
</tr>
<tr>
<td>EDD</td>
<td>end diastolic diameter</td>
</tr>
<tr>
<td>ESD</td>
<td>end systolic diameter</td>
</tr>
<tr>
<td>g</td>
<td>gravity</td>
</tr>
<tr>
<td>g/l</td>
<td>grams per litre</td>
</tr>
<tr>
<td>GH</td>
<td>growth hormone</td>
</tr>
<tr>
<td>h</td>
<td>hour</td>
</tr>
<tr>
<td>HCl</td>
<td>hydrochloric acid</td>
</tr>
<tr>
<td>125I</td>
<td>iodine-125</td>
</tr>
<tr>
<td>131I</td>
<td>iodine-131</td>
</tr>
<tr>
<td>iv</td>
<td>intravenous</td>
</tr>
<tr>
<td>IGF</td>
<td>insulin-like growth factor</td>
</tr>
<tr>
<td>IGF-I</td>
<td>insulin-like growth factor I</td>
</tr>
<tr>
<td>IGF-II</td>
<td>insulin-like growth factor II</td>
</tr>
<tr>
<td>IGFBP</td>
<td>insulin-like growth factor binding protein</td>
</tr>
<tr>
<td>kDa</td>
<td>kilo Dalton</td>
</tr>
<tr>
<td>LAD</td>
<td>left anterior descending (coronary artery)</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricle</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>LVEDD</td>
<td>left ventricular end diastolic diameter</td>
</tr>
<tr>
<td>LVESD</td>
<td>left ventricular end systolic diameter</td>
</tr>
<tr>
<td>M</td>
<td>molar, moles per litre</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>m</td>
<td>metre</td>
</tr>
<tr>
<td>mM</td>
<td>millimolar, millimoles per litre</td>
</tr>
<tr>
<td>mm</td>
<td>millimetre</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mg/ml</td>
<td>milligrams per millilitre</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>MGF</td>
<td>mechanogrowth factor</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger ribonucleic acid</td>
</tr>
<tr>
<td>MSA</td>
<td>multiplication stimulating activity</td>
</tr>
<tr>
<td>MW</td>
<td>molecular weight</td>
</tr>
<tr>
<td>nmol</td>
<td>nanomolar, nanomoles per litre</td>
</tr>
<tr>
<td>NSILA</td>
<td>non-suppressible insulin-like activity</td>
</tr>
<tr>
<td>N-terminal</td>
<td>amino terminal</td>
</tr>
<tr>
<td>P</td>
<td>probability</td>
</tr>
<tr>
<td>pH</td>
<td>hydrogen ion concentration</td>
</tr>
<tr>
<td>PAGE</td>
<td>polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline</td>
</tr>
<tr>
<td>PMSF</td>
<td>phenyl methyl sulphonyl fluoride</td>
</tr>
<tr>
<td>PTCA</td>
<td>percutaneous transluminal coronary angioplasty</td>
</tr>
<tr>
<td>r</td>
<td>recombinant</td>
</tr>
<tr>
<td>rh</td>
<td>recombinant human</td>
</tr>
<tr>
<td>ro</td>
<td>recombinant ovine</td>
</tr>
<tr>
<td>RIA</td>
<td>radioimmunoassay</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>RV</td>
<td>right ventricle</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulphate</td>
</tr>
<tr>
<td>SED</td>
<td>standard error of the difference</td>
</tr>
<tr>
<td>SEM</td>
<td>standard error of the mean</td>
</tr>
<tr>
<td>SERCA</td>
<td>sarcoplasmic reticulum calcium ATP-ase</td>
</tr>
<tr>
<td>TCA</td>
<td>trichloroacetic acid</td>
</tr>
<tr>
<td>vol</td>
<td>volume</td>
</tr>
<tr>
<td>v/v</td>
<td>volume per volume</td>
</tr>
<tr>
<td>w/v</td>
<td>weight per volume</td>
</tr>
</tbody>
</table>
This Thesis Is Dedicated To

My Wife, Barbara,

Without Whose Love, Patience and Understanding,

These Studies

Would Never Have Been Completed